Cross-Sector entity
Outsourcing in Clinical Trials Conference is most often covered alongside Chinese biotech industry, which appears in 2 of these 2 stories. clinical-trial accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Outsourcing in Clinical Trials Conference appears in 2 tracked Cross-Sector stories from June 24, 2026.
2 verified stories tracked
Last mentioned: Jun 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Outsourcing in Clinical Trials Conference is most often covered alongside Chinese biotech industry, which appears in 2 of these 2 stories. clinical-trial accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Outsourcing in Clinical Trials Conference appears in 2 tracked Cross-Sector stories from June 24, 2026. The tracked stories average 2 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Outsourcing in Clinical Trials Conference. Shared-story counts are live from our verified record — not editorial picks.
NMPA releases 2025 report
China's National Medical Products Administration publishes comprehensive statistics on the record-breaking clinical trial activity.
Cost advantages quantified
At the Outsourcing in Clinical Trials conference in California, China's trial costs were reported 50–60% lower and timelines faster than in the US.
Record trial count achieved
5,215 clinical drug trials registered, more than double 2020, with 57.5% being new drug trials and cancer treatments dominating.
Pre-surge baseline
Approximately 2,600 clinical drug trials registered in China (implied by 2025 doubling).
China’s clinical drug trials hit a record 5,215 in 2025, with costs 50–60% lower than in the US. This surge, driven by Beijing’s biotech ambitions, is reshaping global drug development and raising national security concerns in Washington as Chinese firms gain dominance in cancer and vaccine research.
With 5,215 clinical drug trials registered in 2025, China has more than doubled its pipeline since 2020, with 57.5% focused on novel drugs and cancer treatments topping the list. The rapid expansion and 50–60% cost advantage compared to the US are reshaping the global biopharma landscape, but Washington is scrutinizing implications for drug quality and security.
Source: Julie Zhang (hk) · Julie Zhang (hk)
